JAKi is effective in suppression of immune response in human-mouse xenograft model of LVV.[39] Case series showed that JAKi in combination with GC were able to induce and maintain clinical remission of GCA.[40, 41, 42] In a pilot proof-of-concept study, 15 patients with relapsing GCA were treated with baricitinib; 13/15 patient achieved GC-free remission in 52 weeks observation.[43] Upadacitinib, a JAK1 selective inhibitor is being tested in a phase III trial (NCT03725202) for treating GCA in a 26-week GC tapering regimen. The gene discussed is JAK1; the disease is temporal arteritis.